Drugs / KT502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07564154 | Jul 2026 → Dec 2027 expected | rheumatoid arthritis | Kali Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Kali Therapeutics, Inc. | Results Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress kalitherapeutics.com ↗
In our NHP studies, the molecule proved to be very potent in depleting B-cells, yet it induced only low and transitory cytokine releases. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-05-18 | Kali Therapeutics, Inc. | Kali Therapeutics Announces Oral Presentation of KT502, a Novel CD19 x CD3 T-Cell Engager, at the EULAR 2026 Annual Congress kalitherapeutics.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07564154 ↗ |
| Action | Deplete | “KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3” NCT07564154 ↗ |
| Modality | Monoclonal antibody | “KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3” NCT07564154 ↗ |
| Route | Subcutaneous | “KT502 administered subcutaneously” NCT07564154 ↗ |
| Target | CD19 | “KT502 is a monoclonal antibody that depletes B cells by targeting CD19 and CD3” NCT07564154 ↗ |